CY2468B1 - Pharmaceutical formulations containing darifenacin. - Google Patents

Pharmaceutical formulations containing darifenacin.

Info

Publication number
CY2468B1
CY2468B1 CY0400059A CY0400059A CY2468B1 CY 2468 B1 CY2468 B1 CY 2468B1 CY 0400059 A CY0400059 A CY 0400059A CY 0400059 A CY0400059 A CY 0400059A CY 2468 B1 CY2468 B1 CY 2468B1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical formulations
formulations containing
darifenacin
containing darifenacin
pharmaceutical
Prior art date
Application number
CY0400059A
Other languages
English (en)
Inventor
Thomas Francis Dolan
Michael John Humphrey
Donald John Nichols
Original Assignee
Pfizer Res & Dev
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2468(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev, Pfizer Ltd filed Critical Pfizer Res & Dev
Publication of CY2468B1 publication Critical patent/CY2468B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY0400059A 1995-09-15 2004-08-10 Pharmaceutical formulations containing darifenacin. CY2468B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY2468B1 true CY2468B1 (en) 2005-06-03

Family

ID=10780813

Family Applications (3)

Application Number Title Priority Date Filing Date
CY0400059A CY2468B1 (en) 1995-09-15 2004-08-10 Pharmaceutical formulations containing darifenacin.
CY200500007C CY2005007I1 (el) 1995-09-15 2005-04-14 Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
CY0500059A CY2585B2 (en) 1995-09-15 2005-11-10 Pharmaceutical formulations containing darifenacin

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY200500007C CY2005007I1 (el) 1995-09-15 2005-04-14 Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
CY0500059A CY2585B2 (en) 1995-09-15 2005-11-10 Pharmaceutical formulations containing darifenacin

Country Status (32)

Country Link
US (1) US6106864A (de)
EP (2) EP1245231B1 (de)
JP (1) JP3403203B2 (de)
KR (1) KR100348585B1 (de)
CN (1) CN1303998C (de)
AR (1) AR005231A1 (de)
AT (2) ATE269076T1 (de)
BR (2) BR9610153A (de)
CA (1) CA2230314C (de)
CO (1) CO4750822A1 (de)
CY (3) CY2468B1 (de)
CZ (1) CZ294024B6 (de)
DE (4) DE69626397T2 (de)
DK (2) DK1245231T3 (de)
EG (1) EG23826A (de)
ES (2) ES2188782T3 (de)
FR (1) FR05C0019I2 (de)
GB (1) GB9518953D0 (de)
HU (2) HU227397B1 (de)
IL (1) IL122746A (de)
LU (1) LU91163I2 (de)
MY (1) MY125662A (de)
NL (1) NL300190I2 (de)
NO (2) NO314783B1 (de)
NZ (1) NZ316924A (de)
PL (1) PL185604B1 (de)
PT (1) PT1245231E (de)
RU (1) RU2163803C2 (de)
TR (1) TR199800461T1 (de)
TW (1) TW442300B (de)
WO (1) WO1997009980A1 (de)
ZA (1) ZA967745B (de)

Families Citing this family (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
KR20070091049A (ko) 2002-12-13 2007-09-06 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
MXPA05011643A (es) 2003-04-29 2005-12-15 Pfizer Ltd 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2005033107A1 (en) * 2003-10-03 2005-04-14 Pfizer Limited Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
AU2005223483B2 (en) * 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
AU2005225632B2 (en) * 2004-03-23 2011-08-04 Pfizer Inc. Formamide derivatives useful as adrenoceptor
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
CA2562251C (en) * 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
WO2005123718A2 (en) * 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
ES2314690T3 (es) 2004-08-12 2009-03-16 Pfizer, Inc. Derivados de triazolopiridinilsulfanilo como inhibidores de la map quinasa p38.
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
AU2005276135B2 (en) 2004-08-26 2011-04-28 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
ATE417830T1 (de) * 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
CA2601508C (en) 2005-03-17 2012-01-03 Pfizer, Inc. Cyclopropanecarboxamide derivatives
WO2006103503A1 (en) * 2005-03-28 2006-10-05 Pfizer Japan Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AU2006257647A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
EP1917257A1 (de) * 2005-08-10 2008-05-07 Pfizer Limited Substituierte triazolderivate als oxytocin-antagonisten
ATE506059T1 (de) 2005-09-02 2011-05-15 Theravida Inc Therapie zur behandlung der überaktiven blase
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2051966A2 (de) * 2006-08-09 2009-04-29 Pfizer Products Inc. Heterocyclen als kohlenstoffanhydrasehemer
WO2008031221A1 (en) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
JP5140080B2 (ja) * 2006-09-21 2013-02-06 ラクオリア創薬株式会社 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
US8158650B2 (en) 2006-10-23 2012-04-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
NZ578638A (en) * 2007-02-02 2010-12-24 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009105887A1 (en) * 2008-02-26 2009-09-03 Ernest Puil Cyclic amino acids for the treatment of pain
US20110217387A1 (en) * 2008-05-16 2011-09-08 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
JP5553452B2 (ja) * 2008-05-30 2014-07-16 ユセベ ファルマ ソシエテ アノニム ブリバラセタムを含む医薬組成物
EP2328890B1 (de) * 2008-08-06 2012-01-25 Pfizer Inc. 6-substituierte 2-heterocyclylaminopyrazinverbindungen als chk-1-inhibitoren
EP2163253B1 (de) 2008-09-15 2013-07-17 ULLRICH, Oliver Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
CA2741511C (en) 2008-11-21 2017-01-24 Raqualia Pharma Inc. Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
AP2811A (en) 2009-01-12 2013-12-31 Icagen Inc Sulfonamide derivatives
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
EP2233502A1 (de) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
EP2236516A1 (de) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptide und deren Verwendung zur Behandlung von traumatischer oder degenerativer Nervenläsion
EP2435462A1 (de) 2009-05-29 2012-04-04 Pfizer Limited Neue glucocorticoidrezeptoragonisten
EP2266563A1 (de) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
BR112012013801A2 (pt) 2009-12-11 2019-09-24 Du Pont composto,método para inibir a atividade de hidrolase de amida de ácido graxo em um indivíduo,composição farmacêutica e método para tratar um individuo com dor
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
MA33909B1 (fr) 2009-12-23 2013-01-02 Takeda Pharmaceutical Pyrrolidinones accoles en tant d'inhibiteurs de syk
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2566858A2 (de) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclische derivate als alk-hemmer
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593433B1 (de) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
WO2012007861A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
EP2463289A1 (de) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2489663A1 (de) 2011-02-16 2012-08-22 Almirall, S.A. Verbindungen als Syk-Kinasehemmer
ES2533042T3 (es) 2011-02-25 2015-04-07 Takeda Pharmaceutical Company Limited Oxazinopteridinas y oxazinopteridinonas N-sustituidas
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
GEP20156417B (en) 2011-04-05 2015-12-25 Pfizer Ltd Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EP2518071A1 (de) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridinderivate als PI3K-Inhibitoren
EP2518070A1 (de) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinonderivate als PI3K-Inhibitoren
US20120289562A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
EP2706997B1 (de) 2011-05-10 2019-03-27 TheraVida, Inc. Kombinationen aus solifenacin und pilocarpin zur behandlung von hyperaktiver blase
EP2710002B1 (de) 2011-05-18 2017-03-01 RaQualia Pharma Inc Polymorphe form von 4-{[4-({[4-(2,2,2-trifluorethoxy-)1,2-benzisoxazol-3-yl-]oxy-}methyl-)piperidin-1-yl-]methyl-}tetrahydro-2h-pyran-4-carbonsäure
EP2526945A1 (de) 2011-05-25 2012-11-28 Almirall, S.A. Neue CRTH2-Antagonisten
EP2527344A1 (de) 2011-05-25 2012-11-28 Almirall, S.A. Als Medikamente zur Behandlung von myeloproliferativen Krankheiten, Transplantatabstossung, immunbedingten und entzündlichen Erkrankungen geeignete Pyridin-2(1H-)-on-Derivate
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2548876A1 (de) 2011-07-18 2013-01-23 Almirall, S.A. Neue CRTH2-Antagonisten
EP2548863A1 (de) 2011-07-18 2013-01-23 Almirall, S.A. Neue CRTH2-Antagonisten
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (de) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
KR20140041906A (ko) 2011-08-02 2014-04-04 화이자 인코포레이티드 암의 치료에 사용하기 위한 크리조티닙
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
MX2014004743A (es) 2011-10-19 2014-08-01 Zoetis Llc Uso de derivados de aminoacetonitrilo contra endoparasitos.
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
EP2800740A1 (de) 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonyl-benzamide
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
BR112014022106B1 (pt) 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
WO2013152135A1 (en) 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
WO2014039831A1 (en) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
JP6463680B2 (ja) 2012-09-18 2019-02-06 ジアルコ ファーマ リミテッドＺｉａｒｃｏ Ｐｈａｒｍａ Ｌｔｄ 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014053967A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
US20150291625A1 (en) 2012-11-08 2015-10-15 Pfizer Inc. Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
WO2014080633A1 (en) 2012-11-21 2014-05-30 Raqualia Pharma Inc. Polymorph forms
EA026562B1 (ru) 2012-12-03 2017-04-28 Пфайзер Инк. Новые селективные модуляторы андрогенных рецепторов
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
WO2014128588A1 (en) 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US20160022661A1 (en) * 2013-03-13 2016-01-28 Ratiopharm Gmbh Dosage Form Comprising Crizotinib
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
EP2792360A1 (de) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
US9603934B2 (en) 2013-05-17 2017-03-28 Acupac Packaging, Inc. Anhydrous hydrogel composition and delivery system
TR201907981T4 (tr) 2013-06-27 2019-06-21 Pfizer Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı.
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
UY35945A (es) 2014-01-09 2015-08-31 Takeda Pharmaceutical Derivados de azaindol
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
EP3131891A1 (de) 2014-04-15 2017-02-22 Pfizer Inc. Tropomysin-verwandte kinaseinhibitoren mit einer 1h-pyrazol- sowie pyrimidineinheit
AP2016009512A0 (en) 2014-04-25 2016-10-31 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EA201691831A1 (ru) 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3137469B1 (de) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclische verbindungen und deren verwendung als dopamin-d1-liganden
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
MX2016014878A (es) 2014-05-14 2017-03-08 Pfizer Pirazolopiridinas y pirazolopirimidinas.
WO2015173684A1 (en) 2014-05-15 2015-11-19 Pfizer Inc. Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
JP6572414B2 (ja) 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
EP3148992A1 (de) 2014-05-30 2017-04-05 Pfizer Inc. Benzolsulfonamide als kaliumkanalhemmer
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
EP3521285A1 (de) 2014-06-17 2019-08-07 Pfizer Inc Substituierte dihydroisochinolinonverbindungen
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
UY36530A (es) 2015-01-22 2016-08-31 Phytoplant Res S L Métodos para purificar cannabinoides, composiciones y kits de estos
KR20170119705A (ko) 2015-02-24 2017-10-27 화이자 인코포레이티드 항암제로서 유용한 치환된 뉴클레오시드 유도체
EP3268046A4 (de) 2015-03-13 2018-11-21 Endocyte, Inc. Konjugate zur behandlung einer erkrankung
US10214509B2 (en) 2015-04-21 2019-02-26 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
KR102369405B1 (ko) 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
EP3386983A1 (de) 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
SG11201805331QA (en) 2015-12-24 2018-07-30 Takeda Pharmaceuticals Co Cocrystal, production method thereof, and medicament containing cocrystal
US10435388B2 (en) 2016-01-07 2019-10-08 Cs Pharmatech Limited Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
RU2712455C1 (ru) 2016-01-15 2020-01-29 Пфайзер Инк. 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3
CA3011683C (en) 2016-01-20 2023-09-26 Theravida, Inc. Methods and compositions for treating hyperhidrosis
EP3426772A4 (de) 2016-03-09 2019-08-28 Beijing Percans Oncology Co. Ltd. Tumorzellsuspensionskulturen und zugehörige verfahren
CN109071496B (zh) 2016-03-31 2021-07-30 武田药品有限公司 异喹啉基三唑酮复合物
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
JP2019527738A (ja) 2016-08-12 2019-10-03 ナンジン ゲイター メディテック カンパニー, リミテッドNanjing Gator Meditech Company, Ltd. プロテインキナーゼ調節剤
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3558950B1 (de) 2016-12-20 2023-05-10 Oligomerix, Inc. Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
EP3571191A1 (de) 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamatderivate als magl-inhibitoren
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
AU2018211561B2 (en) 2017-01-24 2020-04-30 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
TWI799426B (zh) 2017-06-22 2023-04-21 英商克拉德夫製藥有限公司 人類ｓｔｉｎｇ之小分子調節劑
BR112020004047A2 (pt) 2017-08-30 2020-09-01 Beijing Xuanyi Pharmasciences Co., Ltd dinucleotídeos cíclicos como estimuladores de moduladores de genes interferon
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
SG11202003477QA (en) 2017-11-14 2020-05-28 Pfizer Ezh2 inhibitor combination therapies
MX2020007960A (es) 2018-01-29 2020-09-24 Phytoplant Res S L Metodos para purificar cannabinoides usando cromatografia liquido-liquido.
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
BR112020021689B1 (pt) 2018-04-26 2023-02-28 Pfizer Inc Composto, composição farmacêutica e uso de um composto
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
SG11202100021TA (en) 2018-07-19 2021-01-28 Pfizer Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
BR112021013019A2 (pt) 2019-01-23 2021-09-14 Pfizer Inc. Forma polimórfica de um sal de hidrato de monofosfato de um derivado de tetra-hidroisoquinolina conhecido
WO2020157652A2 (en) 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
AU2020228047A1 (en) 2019-02-27 2021-09-30 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AR118471A1 (es) 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
SG11202111717XA (en) 2019-04-29 2021-11-29 Solent Therapeutics Llc 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021014415A2 (en) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CA3150508A1 (en) 2019-09-16 2021-03-25 Holger Monenschein Azole-fused pyridazin-3(2h)-one derivatives
CA3166358A1 (en) 2020-02-12 2021-08-19 Monali BANERJEE Small molecule sting antagonists
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
IL296998A (en) 2020-04-08 2022-12-01 Mission Therapeutics Ltd N-cyanopyrrolidines with activity as usp30 inhibitors
CR20220548A (es) 2020-05-01 2022-12-12 Pfizer Compuestos de azalactama como inhibidores de hpk1
EP4146625A1 (de) 2020-05-04 2023-03-15 Takeda Pharmaceutical Company Limited Luminal wirkende n-(piperidin-4-yl)benzamidderivate
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
EP4157834B1 (de) 2020-05-28 2024-07-03 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamid-derivate und die entsprechenden oxadiazol-derivate als usp30 inhibitoren zur behandlung von mitochondrialer dysfunktion
IL298710A (en) 2020-06-04 2023-02-01 Mission Therapeutics Ltd N-cyanopyrrolidines with activity as USP30 inhibitors
KR20230022215A (ko) 2020-06-08 2023-02-14 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
EP4181919A1 (de) 2020-07-20 2023-05-24 Pfizer Inc. Kombinationstherapie
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
US20240000783A1 (en) 2020-08-13 2024-01-04 Pfizer Inc. Combination therapy
EP4214202A1 (de) 2020-09-15 2023-07-26 Pfizer Inc. Feste formen eines cdk4-inhibitors
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
JP2023554521A (ja) 2020-12-22 2023-12-27 ファイザー・インク Ｅｉｆ４ｅ阻害剤の固体形態
WO2022137106A1 (en) 2020-12-24 2022-06-30 Pfizer Inc. Solid forms of a cdk2 inhibitor
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
EP4313151A1 (de) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1-inhibitoren und ras-inhibitoren zur verwendung bei der behandlung von schmerzen
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
EP4320121A2 (de) 2021-04-07 2024-02-14 LifeArc 2,4-diaminopyrimidinderivate als ulk1/2-inhibitoren und deren verwendung
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
JP7511097B1 (ja) 2021-06-26 2024-07-04 アレイ バイオファーマ インコーポレイテッド Ｈｅｒ２変異阻害薬
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
TW202321231A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 作為sting拮抗劑之小分子尿素衍生物
CA3228528A1 (en) 2021-08-11 2023-02-16 Monali BANERJEE Small molecule sting antagonists
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023099072A1 (en) 2021-12-01 2023-06-08 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
CA3241001A1 (en) 2021-12-02 2023-06-08 Pfizer Inc Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
WO2023187677A1 (en) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
WO2024013567A1 (en) 2022-07-15 2024-01-18 Jazz Pharmaceuticals Ireland Limited Biaryl ether urea compounds as faah inhibitors
WO2024023727A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Novel acc inhibitors
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
WO2024105364A1 (en) 2022-11-15 2024-05-23 Curadev Pharma Ltd Heterocyclic inhibitors of cdc-like kinases
WO2024150170A1 (en) 2023-01-13 2024-07-18 Neurim Pharmaceuticals (1991) Ltd. Piromelatine for treating parasomnias associated with loss of rem sleep atonia
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
LU91163I2 (fr) 2005-06-20
FR05C0019I1 (de) 2005-05-27
IL122746A (en) 2000-12-06
US6106864A (en) 2000-08-22
NZ316924A (en) 1999-06-29
IL122746A0 (en) 1998-08-16
MX9802026A (es) 1998-08-30
AU703866B2 (en) 1999-04-01
EP1245231A2 (de) 2002-10-02
BR122012014331B8 (pt) 2021-05-25
BR122012014331A2 (de) 1999-01-05
PL185604B1 (pl) 2003-06-30
CY2005007I2 (el) 2009-11-04
TW442300B (en) 2001-06-23
BR122012014331B1 (pt) 2019-10-08
ATE269076T1 (de) 2004-07-15
AR005231A1 (es) 1999-04-28
KR19990044653A (ko) 1999-06-25
EP1245231A3 (de) 2003-01-15
CA2230314A1 (en) 1997-03-20
TR199800461T1 (xx) 1998-05-21
PT1245231E (pt) 2004-10-29
RU2163803C2 (ru) 2001-03-10
DE69632753D1 (de) 2004-07-22
DE69626397D1 (de) 2003-04-03
CY2585B2 (en) 2009-11-04
CO4750822A1 (es) 1999-03-31
PL325598A1 (en) 1998-08-03
HUP9802339A2 (hu) 1999-08-30
ATE233090T1 (de) 2003-03-15
EP1245231B1 (de) 2004-06-16
CN1195984A (zh) 1998-10-14
ES2188782T3 (es) 2003-07-01
EP0850059A1 (de) 1998-07-01
CN1303998C (zh) 2007-03-14
AU6927596A (en) 1997-04-01
CZ73298A3 (cs) 1999-03-17
HU0500976D0 (en) 2005-12-28
BR122012014331A8 (pt) 2018-07-31
MY125662A (en) 2006-08-30
JP3403203B2 (ja) 2003-05-06
DE69632753T2 (de) 2005-07-14
DK1245231T3 (da) 2004-10-25
DE122005000024I1 (de) 2005-08-04
DK0850059T3 (da) 2003-03-31
HU225236B1 (en) 2006-08-28
CZ294024B6 (cs) 2004-09-15
KR100348585B1 (ko) 2002-10-31
FR05C0019I2 (de) 2005-11-04
DE122005000024I2 (de) 2006-11-23
CY2005007I1 (el) 2009-11-04
NO314783B1 (no) 2003-05-26
HUP9802339A3 (en) 1999-09-28
DE69626397T2 (de) 2003-07-17
ZA967745B (en) 1998-03-13
NL300190I1 (nl) 2005-07-01
HU227397B1 (en) 2011-05-30
JPH10511112A (ja) 1998-10-27
EP0850059B1 (de) 2003-02-26
ES2224002T3 (es) 2005-03-01
NL300190I2 (nl) 2005-08-01
NO981073L (no) 1998-03-11
WO1997009980A1 (en) 1997-03-20
NO2005009I1 (no) 2005-04-18
NO2005009I2 (no) 2006-11-27
NO981073D0 (no) 1998-03-11
EG23826A (en) 2007-09-25
BR9610153A (pt) 1999-01-05
CA2230314C (en) 2003-06-24
GB9518953D0 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
CY2468B1 (en) Pharmaceutical formulations containing darifenacin.
ZA969722B (en) Pharmaceutical formulations.
ZA965190B (en) Pharmaceutical composition.
ZA967034B (en) Pharmaceutical compositions.
GB9408117D0 (en) Pharmaceutical formulations
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
ZA951781B (en) Pharmaceutical formulations
CY2359B1 (en) Pharmaceutical formulation.
ZA968081B (en) Pharmaceutical composition.
GB9502695D0 (en) Pharmaceutical composition
ZA9610589B (en) Pharmaceutical compounds.
ZA96392B (en) Pharmaceutical formulations
ZA967542B (en) Pharmaceutical combination preparation comprising keto-profen
GB9413542D0 (en) Pharmaceutical formulations
GB9500978D0 (en) Pharmaceutical formulations
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
ZA957349B (en) Pharmaceutical formulations.
GB9516584D0 (en) Pharmaceutical formulations
GB9508989D0 (en) Pharmaceutical formulations
GB9503752D0 (en) Pharmaceutical formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations
GB9408162D0 (en) Pharmaceutical formulations
GB9408161D0 (en) Pharmaceutical formulations